A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers Portfolio News / By Karina Tin December 23, 2020
ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101 Portfolio News / By Karina Tin December 21, 2020
NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors Portfolio News / By Karina Tin December 9, 2020
Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition Portfolio News / By Karina Tin December 7, 2020
Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T Portfolio News / By Karina Tin December 7, 2020
Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting Portfolio News / By Karina Tin December 6, 2020
ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Portfolio News / By Karina Tin November 17, 2020
RAPT Therapeutics Reports Positive Initial Data From Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications Portfolio News / By Karina Tin November 16, 2020
RAPT Therapeutics Reports Third Quarter 2020 Financial Results Portfolio News / By Karina Tin November 16, 2020
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy Portfolio News / By Karina Tin November 13, 2020
